These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15844442)

  • 1. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6.
    Manga N; Duffy JC; Rowe PH; Cronin MT
    SAR QSAR Environ Res; 2005; 16(1-2):43-61. PubMed ID: 15844442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
    Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
    Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug metabolism and variability among patients in drug response.
    Wilkinson GR
    N Engl J Med; 2005 May; 352(21):2211-21. PubMed ID: 15917386
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of Robust Quantitative Structure-Activity Relationship Models for CYP2C9, CYP2D6, and CYP3A4 Catalysis and Inhibition.
    Gonzalez E; Jain S; Shah P; Torimoto-Katori N; Zakharov A; Nguyễn ÐT; Sakamuru S; Huang R; Xia M; Obach RS; Hop CECA; Simeonov A; Xu X
    Drug Metab Dispos; 2021 Sep; 49(9):822-832. PubMed ID: 34183376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
    Emoto C; Iwasaki K
    Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Investigation on the hydroxylation metabolism of imrecoxib in vitro by using recombinant human CYPs].
    Li Q; Huang HH; Dong Y; Zhong DF
    Yao Xue Xue Bao; 2005 Oct; 40(10):912-5. PubMed ID: 16408808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism.
    Galetin A; Houston JB
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1220-9. PubMed ID: 16763093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of hydrophobic parameters in identifying appropriate pose of CYP substrates in cytochromes.
    Ramesh M; Bharatam PV
    Eur J Med Chem; 2014 Jan; 71():15-23. PubMed ID: 24269512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
    Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
    J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
    Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
    J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probabilistic prediction of the human CYP3A4 and CYP2D6 metabolism sites.
    Dapkunas J; Sazonovas A; Japertas P
    Chem Biodivers; 2009 Nov; 6(11):2101-6. PubMed ID: 19937844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
    Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
    Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting drug metabolism by cytochrome P450 2C9: comparison with the 2D6 and 3A4 isoforms.
    Rydberg P; Olsen L
    ChemMedChem; 2012 Jul; 7(7):1202-9. PubMed ID: 22593031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.
    Brown HS; Ito K; Galetin A; Houston JB
    Br J Clin Pharmacol; 2005 Nov; 60(5):508-18. PubMed ID: 16236041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
    He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
    Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition.
    Gallemann D; Wimmer E; Höfer CC; Freisleben A; Fluck M; Ladstetter B; Dolgos H
    Drug Metab Dispos; 2010 Jun; 38(6):905-16. PubMed ID: 20219851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Rana P; Will Y; Nadanaciva S; Jones LH
    Bioorg Med Chem Lett; 2016 Aug; 26(16):4003-6. PubMed ID: 27397500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new standardized electrochemical array for drug metabolic profiling with human cytochromes P450.
    Fantuzzi A; Mak LH; Capria E; Dodhia V; Panicco P; Collins S; Gilardi G
    Anal Chem; 2011 May; 83(10):3831-9. PubMed ID: 21469680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.
    Ring BJ; Eckstein JA; Gillespie JS; Binkley SN; VandenBranden M; Wrighton SA
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1044-50. PubMed ID: 11356927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.